A Phase 1/2 interventional study of TRK-950 and TRK-950 in Solid Tumor and Melanoma, sponsored by Toray Industries, Inc. Recruiting at 10 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Toray Industries, Inc · Phase 1/2, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Melanoma with a site in Japan — 9 open to participants now, 19 under way, 3 of them phase 3. Melanoma · Japan.
Among the 65 studies in Melanoma with a site in Japan, this one is the 48th largest by planned enrollment of the 62 interventional ones that give a count, is one of 5 that started in 2022, is one of 10 in phase 1/2, reaches primary completion later than 11 of the 18 other live ones, and was the 50th registered.
3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.
Browse Melanoma studies →9 of the 65 studies in Melanoma with a site in Japan are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Japan, United States, Belgium and 10 more countries
Ages 18+
AstraZeneca · Sites in Japan, United States, Australia and 1 more country
Ages 18+
Daiichi Sankyo · Sites in Japan, United States, Argentina and 15 more countries
Ages 18+
Daiichi Sankyo · Sites in Japan, United States, Australia and 13 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Japan, United States, Australia and 5 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 21 · Phase 3 14 · Phase 4 2
First in 2008; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 49 is above the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 156 across the 62 interventional studies, 82 across the 3 observational. Of the 44 that completed or were terminated, 25 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 65 have an industry lead sponsor. The 10 most frequent:
Toray Industries, Inc is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
Toray Industries, Inc has 2 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
4 of the studies in Melanoma with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03891953Novartis PharmaceuticalsStudy of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | 2027-06-25 |
| NCT06636435Chiome Bioscience Inc.A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer | 2027-06-30 |
| NCT05538130PfizerA Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | 2027-08-31 |
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 65 studies in Melanoma with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Part 1
Part 2
Part 3
This is an open-label phase I/II study and consists of three parts. In Part 1, patients with histologically and cytologically confirmed locally advanced or metastatic solid tumors who have been refractory or intolerant to standard therapies or for whom no standard therapy exists will receive two dose level of TRK-950. In Part 2, patients with histologically and cytologically confirmed locally advanced or metastatic solid tumors who are eligible for standard therapy with NIVO 240 mg alone administered at 2-week intervals will receive two dose level of TRK-950 in combination with Nivolumab. In Part 3, patients with histologically confirmed locally advanced unresectable or metastatic melanoma (excluding uveal melanoma), who received prior chemotherapy with DTIC and for whom no standard therapy exists will receive one dose level of TRK-950. The objectives of this study are to determine the safety, tolerability, pharmacokinetic (PK) profile and the incidence of the development of anti-drug antibodies (ADA) and neutralizing antibodies (NAb) against TRK-950.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who meet any of the following conditions on virus (HBV) and virus (HCV) testing
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Solid Tumor * TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle. Two dose levels will be explored during this Arm.
Biological: TRK-950
* Nivolumab-eligible solid tumor * Nivolumab will be administered intravenously on days 1 and 15 of a 28-day cycle. TRK-950 will be administered as an intravenously infusion on days 1, 8, 15 and 22. After the administration of Nivolumab on days 1 and 15, TRK-950 will be administered as an intravenously infusion.
Biological: TRK-950 · Drug: Nivolumab
* Nivolumab-eligible solid tumor * Nivolumab will be administered intravenously on days 1 and 15 of a 28-day cycle. TRK-950 will be administered as an intravenously infusion on days 1 and 15. After the administration of Nivolumab on days 1 and 15, TRK-950 will be administered as an intravenously infusion.
Biological: TRK-950 · Drug: Nivolumab
* Melanoma * TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle.
Biological: TRK-950
5 or 10 mg/kg administered intravenously over 60 minutes (weekly)
10 mg/kg administered intravenously over 60 minutes (weekly)
20 mg/kg administered intravenously over 60 minutes (bi-weekly)
240 mg administered intravenously over 30 minutes (bi-weekly)
10 mg/kg administered Intravenously over 60 minutes (weekly)
Number of participants with dose-limiting toxicities (DLTs) (Part 1 and 2)
Number of participants with DLTs will be determined.
Time frame: Up to Day 28
Number of participants with adverse events (AEs) (Part 1 and 2)
Number of participants with AEs will be assessed.
Time frame: through study completion, an average of 1 year
Number of participants with adverse events of special interest (AESIs) (Part 1 and 2)
Number of participants with AESIs will be assessed.
Time frame: through study completion, an average of 1 year
Number of participants with serious adverse events (SAEs) (Part 1 and 2)
Number of participants with SAEs will be assessed.
Time frame: through study completion, an average of 1 year
Objective response rate (ORR) (Part 3)
Objective response rate (ORR) is defined as the percentage of patients who achieved either complete response (CR) or partial response (PR) as assessed by independent central review (ICR) per RECIST Version 1.1.
Time frame: Up to approximately 12 months
Area under the concentration curve (AUC) of TRK-950 (Part 1 and 2)
Time frame: through study completion, an average of 1 year
Maximum plasma concentration (Cmax) of TRK-950 (Part 1 and 2)
Time frame: through study completion, an average of 1 year
Time to maximum plasma concentration (Tmax) of TRK-950 (Part 1 and 2)
Time frame: through study completion, an average of 1 year
Terminal elimination half life (t1/2) of TRK-950 (Part 1 and 2)
Time frame: through study completion, an average of 1 year
Total body clearance (CL) of TRK-950 (Part 1 and 2)
Time frame: through study completion, an average of 1 year
Apparent volume of distribution (Vd) of TRK-950 (Part 1 and 2)
Time frame: through study completion, an average of 1 year
Area under the concentration curve (AUC) of Nivolumab (Part 2 only)
Time frame: through study completion, an average of 1 year
Overall survival (OS) (Part 3)
Overall survival (OS) is defined as time from the first date of TRK-950 administration until the date of death due to any cause.
Time frame: Up to approximately 12 months
Progression-free survival (PFS) (Part 3)
Progression-free survival (PFS) is defined as time from the first date of TRK-950 administration until progression per RECIST Version 1.1, or death due to any cause.
Time frame: Up to approximately 12 months
Best overall response (BOR) (Part 3)
Best overall response (BOR) is defined as the best response among all responses at each time point from the first date of TRK-950 administration until progression per RECIST Version 1.1.
Time frame: Up to approximately 12 months
Disease control rate (DCR) (Part 3)
Disease control rate (DCR) is defined as the percentage of patients with BOR of CR or PR or stable disease (SD) per RECIST Version 1.1.
Time frame: Up to approximately 12 months
Duration of response (DOR) (Part 3)
Duration of response (DOR) is defined as the duration between the date of first documented response (CR or PR) and the date of progression per RECIST Version 1.1, or death due to any cause.
Time frame: Up to approximately 12 months
Tumor change rate (Part 3)
Tumor change rate is defined as the percentage change in the sum of the longest diameters of target lesions, as assessed per RECIST Version 1.1, compared to baseline obtained at screening.
Time frame: Up to approximately 12 months
Plan to share: No
Started Jul 2022 (actual). Primary completion is estimated for Mar 2028, 68 months after the start.
Of 135 industry-sponsored phase 1/2 interventional studies under Melanoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 84. This study's planned 68 months is above that.
Counting every sponsor, half of 220 studies reached it within 60 months; a quarter within 42 and three quarters within 85.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Dec 2027 → Mar 2028 and completion Dec 2027 → Mar 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TRK-950
Toray Industries, Inc